Contact SCGE




Gene Therapy Trial Report

Summary

A Clinical Study to Evaluate the Safety, and Tolerability of BBM-P002 in the Treatment of Parkinson's Disease

NCTID NCT07195825 (View at clinicaltrials.gov)
Description
Development Status Active
Indication Parkinson's Disease
Disease Ontology Term DOID:14330
Compound Name BBM-P002
Compound Alias BBM003
Sponsor Shanghai Xinzhi BioMed Co., Ltd.
Funder Type Industry
Recruitment Status
Not yet recruiting
Enrollment Count 18 (ESTIMATED)
Results Posted Not Available

Therapy Information

Target Gene/Variant Undisclosed
Therapy Type Undisclosed
Therapy Route In-vivo
Mechanism of Action Undisclosed
Route of Administration Intraparenchymal
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type AAV
Editor Type
Dose 1 Undisclosed
Dose 2
Dose 3
Dose 4
Dose 5

Study Record Dates

Current Stage Phase1
Submit Date 2025-09-10
Completion Date 2031-12-30
Last Update 2025-09-29

Participation Criteria

Eligible Age 40 Years - 70 Years
Standard Ages Adult, Older adult
Sexes Eligible for Study ALL

Locations

No.of Trial Sites 1
Locations China

Regulatory Information

Has US IND False
FDA Designations
Recent Updates

Resources/Links

Related NCTID